Cytiva Unveils Fibro dT Platform for Enhanced mRNA Purification
Fibro dT platform offers a high-capacity solution for mRNA purification with chromatography cycle times under 15 minutes.
Sustainable performance, with recovery over 80 percent for many chromatography cycles and across different units.
Helps prevent the loss of RNA molecule waste and conserves raw materials.
- Cytiva, a Danaher company and leader in the life sciences industry, has launched its fibro dT platform, for mRNA capture and purification processes.
Because of its unique structure and design, it can handle large amounts of RNA efficiently and speeds the purification process by avoiding the need for the RNA to move into tiny resin beads.
Emmanuel Abate, President of Genomic Medicine at Cytiva, says: “The industry has long sought efficient methods to capture valuable molecules, minimizing waste and maximizing yield. Fibro dT achieves this quickly and cost-effectively, ultimately benefitting patients in need of advanced therapies.”
Cytiva has worked with its fellow Danaher affiliate company, Aldevron, on early versions of this technology to learn more quickly what customers want. Mark Wetzel, VP and General Manager of mRNA Services, Aldevron, says: “By combining Cytiva’s dT20 fiber adsorber and our end-to-end mRNA production, we’re streamlining the journey from research to clinic. Together, we’re raising the bar for flexibility, speed, and reliability in mRNA purification and manufacturing.”
Key Features
- 6 mg/mL mRNA binding capacity (typical 2000‑mer with poly(A) tail)
- < 15 minutes per chromatography cycle (0.4 mL unit)
- High reproducibility across cycles and batches
- Engineered for lower‑salt loading, helping limit precipitation risk and improve impurity clearance
- ÄKTA™‑compatible workflows for streamlined setup and training
Product information: Cytiva™ fibro dT | Cytiva
ÄKTA™ and Fibro™ are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
Media contact:
Colleen Connolly
Colleen.Connolly@cytiva.com
About Cytiva
At Cytiva, a Danaher company, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Original source here.